pharma · Diabetic Macular Edema · Hypercholesterolemia · REGN
Regeneron UK
Regeneron UK Limited
Regeneron UK is a pharma organization headquartered in Tarrytown, USA. It trades on NYSE under ticker REGN. Primary therapeutic focus areas include Diabetic Macular Edema, Hypercholesterolemia, Asthma, Macular Degenerati
Tarrytown, USA HQ
16,715 Employees
Public company Type
REGN · NYSE Ticker
Company details
- Status
- Public
- HQ
- Tarrytown, USA
- Employees
- 16,715
- Programs
- 493
- Drugs
- 98
- Patents
- 837
Pozelimab
Phase 3 · small molecule · CD55-deficient Protein-losing Enteropathy
Pozelimab for CD55-deficient Protein-losing Enteropathy is a Phase 3 program (small_molecule) at Regeneron UK Limited with 1 ClinicalTrials.gov record(s).
Internal code R3918-PLE-1878
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Regeneron UK Limited
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- CD55-deficient Protein-losing Enteropathy
- Status
- completed
- Trials
- 1